A clinical decision support tool that predicts the window of time when a tumor is most likely to develop drug resistance based on its mutation rate.
The PESTEL analysis reveals a high-potential innovation that is strongly supported by technological trends and clinical demand, but faces significant hurdles in regulatory approval and the high cost of genomic data integration. The tool's success depends on transitioning from a theoretical mathematical model to a validated clinical standard.
Political2
Economic3
Social2
Technological3
Environmental2
Legal3
The viability of a clinical decision tool depends heavily on healthcare regulations, medical ethics, and technological integration within hospital systems. · Generated 2026-08-18 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated